Receptor Life Sciences said that a Phase 1b/2a trial of its RLS103 cannabidiol DPI in social anxiety disorder patients with acute anxiety has gotten underway. The trial is expected to enroll approximately 30 patients who will get either 3 mg of RLS103, 6 mg of RLS103, or an inhaled dry powder placebo prior to a public speaking challenge.
The RLS103 formulation includes synthetic CBD and is based on MannKind’s Technosphere particle engineering technology. The formulation is delivered via MannKind’s Dreamboat DPI device. Earlier this year, Receptor announced that it had raised in a $9.7 million Series A-1 financing round for clinical development of the DPI.
Receptor Life Sciences President and CEO Mark Theeuwes commented, “Advancing the clinical development of RLS103 and dosing the first patient marks a key milestone for our company. With no acute therapies currently available, RLS103 has the potential to offer immediate relief, in three minutes or less, for patients living with social anxiety. We expect to report topline results by early 2023.”
Read the Receptor Life Sciences press release.
